Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KURA ONCOLOGY, INC.

(KURA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kura Oncology : Credit Suisse Lowers Kura Oncology's PT to $40 from $42, Updates Model with Q2 Actuals, Adjusts KO-539 Launch Trajectory Assumptions; Keeps Outperform Rating

08/06/2021 | 10:51am EST


ę MT Newswires 2021
All news about KURA ONCOLOGY, INC.
11/26Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Ra..
MT
11/24Health Care Stocks Unable to Return to Positive Ground By Wednesday Close
MT
11/24Kura Oncology Shares Sink After FDA Imposes Partial Hold on Phase 1b Study of KO-539
MT
11/24Health Care Stocks Marginally Lower After Paring Losses
MT
11/24HC Wainwright Adjusts Price Target on Kura Oncology to $32 From $43, Maintains Buy Rati..
MT
11/24Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical..
MT
11/24Wall Street Set to Open in Red Territory; US GDP Growth Upwardly Revised in Q3
MT
11/24Health Care Stocks Mixed Premarket Wednesday
MT
11/24Health Care
MT
11/24Top Premarket Decliners
MT
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -134 M - -
Net cash 2021 497 M - -
P/E ratio 2021 -6,91x
Yield 2021 -
Capitalization 932 M 932 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 116
Free-Float 94,3%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 14,01 $
Average target price 38,43 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President & Chief Executive Officer
Marc Edward Grasso Chief Financial & Business Officer
Mollie Leoni Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-57.12%932
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678